JW Pharmaceutical has introduced Gan & Lee’s GLP-1 drug bofanglutide in a deal worth a total of $81.1 million (approximately 117.5 billion won). The company will pay a $5 million upfront fee and has secured exclusive rights in South Korea to develop and commercialize the drug for
2026-05-15
Results from a U.S. phase 1/2a trial of Kolon Life Science’s neuropathic pain treatment ‘KLS-2031’ have been accepted for publication in an academic journal. The trial involved a single administration of a gene therapy carrying three therapeutic genes to 18 patients. The company
2026-05-15
Dongsung Pharmaceutical has been sued by Apple of the Eye for approximately 1.7 billion won in damages, an amount equivalent to 7.2% of its equity. The plaintiff, Apple of the Eye, filed the lawsuit with the Seoul Central District Court, naming Dongsung Pharmaceutical and DS ENS
2026-05-15
Hanmi Pharmaceutical’s rare disease drug candidate ‘efpeglenatide’ has received U.S. FDA Breakthrough Therapy Designation (BTD) as a treatment for congenital hyperinsulinism. The once-weekly formulation incorporates the LAPSCOVERY platform technology, and a global phase 2 clinica
2026-05-15
JW Shinyak will jointly develop AD-303, an LNP-based topical treatment for hair loss. Through an agreement with Mujinmedi, the company secured exclusive domestic sales rights for 10 years after launch. The new drug is intended to minimize the systemic adverse effects associated w
2026-05-15
Kolon TissueGene has completed dosing in a total of 1,066 patients in the U.S. Phase 3 trial of its osteoarthritis treatment ‘TG-C.’ The trial consists of two pivotal studies and will include 2 years of follow-up from the date of the final dose to evaluate TG-C’s efficacy as a di
2026-05-15
Kukje Pharma invested 1.76 billion won in first-quarter R&D expenses for four pipeline candidates, including a phase 3 improved glaucoma drug. The most advanced candidate, the three-drug glaucoma combination TFC-003, is in phase 3 clinical development, while an anti-inflammatory
2026-05-15
The U.S. FDA has accepted Ildong Pharmaceutical’s new drug application (NDA) for the postexposure prophylaxis indication of Xocova, an oral COVID-19 treatment under development, setting June 16 as the target action date under the Prescription Drug User Fee Act (PDUFA). Xocova wor
2026-05-15
Yuhan Corp.’s lung cancer drug Leclaza, used in combination therapy, secured regulatory approval in five major markets, including the United States and Europe, within one year. As a result, the company received a $60 million milestone payment, approximately 87 billion won, from J
2026-05-15
Ilyang Pharmaceutical’s quadrivalent influenza vaccine, Teratect, has been approved for administration to infants and young children aged 6 months to younger than 3 years, making vaccination available for all age groups. In addition, the leukemia treatment Suppect has completed a
2026-05-15
